Novel FEN1 Inhibitor with Unique Metal-Binding Pharmacophore to Enhance Synergistic Therapeutic Effects with USP1, PARP, PARG, & ATR Inhibitors
Time: 9:00 am
day: Day Two
Details:
- Highlighting the discovery of BSM-1516, a novel and highly potent FEN1 inhibitor, demonstrating significant selectivity and efficacy, especially against HR-deficient cancer cells—a breakthrough overcoming previous chemistry limitations
- Presenting evidence of strong synergy between BSM-1516 and multiple DDR drug classes (e.g., PARP, PARG, USP1, ATR inhibitors), underscoring its potential to enhance the therapeutic effects of existing DDR-targeting treatments
- Showcasing ongoing in vivo studies that build on preclinical data, positioning BSM-1516 for future clinical testing, particularly in combination with synergistic DDR inhibitors
